Analyst upgrades:

• Keefe Bruyette upgraded KeyCorp (NYSE: KEY) to Outperform from Market Perform due to valuation and the company's capital position. The firm has an $8 target price on the stock.
• BofA/Merrill upgraded its view of the semiconductor sector and upgraded Intel (NASDAQ: INTC) and Marvell Technology (NASDAQ: MRVL) to Buy from Neutral, LSI Corp. (NYSE: LSI) to Buy from Underperform, and Maxim (NASDAQ: MXIM) and National Semiconductor (NYSE: NSM) to Neutral from Underperform. The firm now sees 2010 revenue growth of 21% vs. its prior estimate of 14% due to improving electric demand and lean inventories.
• Thomas Weisel upgraded Vital Images (NASDAQ: VTAL) to Overweight from Market Weight based on compelling valuation and potential upside from its new ViTAL Enterprise product offering.
• Jones Apparel (NYSE: JNY) was upgraded to Buy from Neutral at Goldman.
• Hess Corp. (NYSE: HES) was upgraded to Overweight from Equal Weight at Barclays.
• Nationwide Health (NYSE: NHP) was upgraded to Outperform from Market Perform at Morgan Keegan.

Analyst upgrades:

• Citigroup upgraded Blue Nile (NASDAQ: NILE) shares to Buy from Hold on valuation following the recent sell-off as they believe weakening fundamentals have been factored into estimates and that Blue Nile should benefit from the recent softening of diamond prices. The firm raised its target price to $30 from $20.
  
• Baird upgraded AmSurg (NASDAQ: AMSG) to Outperform from Neutral based on valuation, potential upside from in-line results, good visibility, and FCF yield.
  
• Oppenheimer upgraded DryShips (NASDAQ: DRYS) to Perform from Underperform on valuation following the recent weakness and believes the company is at least halfway through its $500M equity offering.
• UAL Corp (NASDAQ: UAUA) was raised to Buy from Neutral at Banc of America/Merrill.
  
• Mylan (NASDAQ: MYL) was upgraded to Overweight from Equal Weight at Barclays.
  
• Exxon Mobil (NYSE: XOM) was lifted at Deutsche Bank to Buy from Hold.

Analyst upgrades:

• Baird upgraded Fifth Third Bancorp (NASDAQ: FITB), SunTrust (NYSE: STI) and Wells Fargo (NYSE: WFC) to Outperform from Neutral citing the ability to raise cheap capital following the Treasury's aggressive policy response.
  
• Keefe Bruyette upgraded First Security Group (NASDAQ: FSGI), Amcore Financial (NASDAQ: AMFI) and Seacoast Banking (NASDAQ: SBCF) to Outperform from Market Perform to reflect the benefits of the government's TARP program.
  
• Suntrust believes Zions Bancorp (NASDAQ: ZION) is disproportionately positioned to benefit from what should be a wave of industry fallout and consolidation over the next few years. Shares were upgraded to Buy from Neutral.
• Cadbury (NYSE: CBY) was raised to Hold from Sell at ING Group.
  
• Ericsson (NASDAQ: ERIC) was raised to Neutral from Sell at Goldman.
  
• Genentech (NYSE: DNA) was upgraded at Piper Jaffray to Buy from Neutral.

Analyst downgrades:

MOST NOTEWORTHY: Today's noteworthy initiations were Monolithic Power, Emergency Medical Services, Amsurg and EnergySolutions.

• Monolithic Power (NASDAQ: MPWR) was initiated with a Buy at Am Tech, which predicted that Monolithic Power will have significant design win momentum that should result in stronger than expected revenue growth. The firm thinks the company will be able to grow 20% in its 2008, thanks to its new products and competitive prices.
  
• Emergency Medical Services (NYSE: EMS) was initiated with a Sell, target $15 at Citigroup. Citigroup believes EMS's earnings contribution from insurance releases and prior period adjustments is not sustainable.
  
• AMSurg (NASDAQ: AMSG) was initiated with a Buy, target $32 at Citigroup. Citigroup said it is positive on AMSurg given its history of FCF per share growth, low out of network exposure, little debt risk, and acquisition pipeline.
  
• EnergySolutions (NYSE: ES) was initiated with a Market Perform, target $26 at FBRC. Friedman Billings expects EnergySolutions to trade at a slight discount to peers given its leverage balance sheet and perceived slower growth.

OTHER INITIATION:

• VMWare (NYSE: VMW) initiated with a Market Weight at Thomas Weisel, based on valuation. Thomas Weisel believes VMWare is uniquely positioned to benefit from trends toward centralized IT resources, on-demand delivery and greater efficiency.
• Citrix Systems (NASDAQ: CTXS) was initiated with an Overweight, target $37 at Thomas Weisel. Thomas Weisel believes Citrix Systems is uniquely positioned to benefit from trends toward centralized IT resources and on-demand delivery given its product line that targets the data center.

MOST NOTEWORTHY: Apollo Group, Zoran, AmSurg Corp, Apple and Tribune Co were today's noteworthy upgrades:

• Baird upgraded shares of Apollo Group (NASDAQ: APOL) to Outperform from Neutral based on positive enrollment and revenue trends, margin improvement, and a strategic international announcement.
  
• CIBC upped its rating on Zoran Corporation (NASDAQ: ZRAN) to Sector Outperformer from Sector Performer following strong Q3 results and guidance.
  
• Jefferies upgraded shares of AmSurg Corp (NASDAQ: AMSG) to Buy from Hold as they believe the new CEO is preparing to drive earnings growth through acquisitions.
  
• ThinkEquity continues to expect Apple (NASDAQ: AAPL) to outpace the industry in growth. The firm upgraded shares to Buy from Accumulate.
  
• Barrington upgraded shares of Tribune Company (NYSE: TRB) to Market Perform from Underperform on valuation, as they believe the current price significantly discounts the risks of the going private transaction getting done.

OTHER UPGRADES:

• Citigroup upgraded Jarden Corporation (NYSE: JAH) and Teradyne (NYSE: TER) to Buy from Hold.
  
• Lehman upgraded SunPower Corporation (NASDAQ: SPWR) to Overweight from Equal Weight.
  
• HSBC upgraded ArcelorMittal (NYSE: MT) to Overweight from Underweight.
  
• WestLB raised Roche Holding (OTC: RHHBY) to Add from Hold.

When you need surgery, particularly something on an outpatient basis, you want to deal with experienced folks who keep costs in mind. There's a company in Nashville, Tennessee that operates under a business model designed to satisfy that desire.

AmSurg Corporation (NASDAQ:AMSG) operates 163 outpatient ambulatory surgery centers across the United States. The facilities are generally equipped and staffed for a single medical specialty and are typically located in, or adjacent to, a physician group practice. The specialties involve high-volume, low-risk procedures, including colonoscopies, cataract surgeries, knee arthroscopies, carpal tunnel repairs and tonsillectomies. Relatively low development costs, efficient staffing and an operating environment focused on cost containment contribute to the firm's ability to offer cost-effective alternatives to other surgery settings.

The company pleased investors last week, when it announced Q4 EPS of 32 cents and revenues of $118.9 million. Analysts had been looking for 32 cents and $116.6 million. Management also guided Q1 EPS to 35-36 cents (31 cent consensus), FY07 EPS to $1.43-$1.45 ($1.39 consensus) and FY07 revenues to $510-$530 million ($509.70M consensus). The CEO reported fourth quarter same-center revenue growth of three percent (yr/yr), noting that it was the 36th consecutive quarter in which the company had recorded an increase. The share price popped above 200-day moving average resistance on the news and has since been defining a bullish "flag" consolidation pattern. Stocks frequently exit flags moving in the same direction they were traveling when they entered them. In this case, that would be to the upside.

Brokers recommend the shares with two "strong buys," one "buy," thirteen "holds" and three "sells." Analysts see a 15% average annual growth rate, through the next five years. The AMSG P/E ratio (19.31), Price to Sales ratio (1.56), Price to Cash Flow ratio (13.06), Sales Growth rate (16.64%) and Operating Margin (35.12%) compare favorably with industry, sector and S&P 500 averages.

Institutions hold about 95% of the outstanding shares. The stock is one of those used to calculate the S&P 600 SmallCap Index. Over the past 52 weeks, it has traded between $19.68 and $27.00. A stop-loss of $21.20 looks good here.

Larry Schutts is a contributing editor for Theflyonthewall.com and the Vice-President of Stockwinners.com.